SMAD3 and scleroderma: Furthermore, WKYMVm treatment did not reduce the numbers of Vimentin+ or Vimentin+p-SMAD3+ myofibroblasts in the scleroderma skin of Fpr2 KO mice, in contrast to the significant inhibition of those in the scleroderma skin of wild type mice (Figures 6B,D,E).